A new investigational treatment has shown strong and lasting responses in multiple myeloma patients with extramedullary ...

EDX Medical Group has entered into an agreement with Spire Healthcare Group to advance diagnostic innovations aimed at ...

UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) ...

Santen has announced that the European Commission has granted market authorisation for Ryjunea, a low-dose atropine eye drop ...

Argenx has presented positive phase 2 results for efgartigimod in myositis and Sjogren’s disease at EULAR 2025. The company ...

Levicept has presented new data from its phase 2 trial of LEVI-04 at the European Congress of Rheumatology (EULAR 2025). The ...

The PharmaTimes Clinical Researcher of the Year – The Americas 2025 Awards offer an unparalleled opportunity to showcase your ...

In a move to progress treatment efficacy, oncologists widely agree that, in the future, cancer treatments will become ...

Birmingham spin-out Linear Diagnostics has secured £1m funding to advance a rapid test for sexually transmitted infections ...

The European Migraine and Headache Alliance (EMHA) has urged EU policymakers to include migraine in the forthcoming ...

Tagomics has been awarded £860k in funding from Innovate UK’s Biomedical Catalyst programme to develop a novel diagnostic ...

Sogroya acts as a replacement for endogenous growth hormone and is administered once a week to support growth in children ...